The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Personalizing chemotherapy in PDAC with AI-assisted transcriptomic signatures
Nelson Dusetti, PhD, Cancer Research Centre of Marseille, Marseille, France, provides an overview of the development of an artificial intelligence (AI)-assisted transcriptomic signature to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma (PDAC). Due to the heterogenous nature of pancreatic cancer, the molecular characteristics are often not taken into account in decision making. The newly created transcriptomic signature will subsequently be validated in a cohort of patients randomized to receive either gemcitabine or FOLFIRINOX. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Predicting Med
Patents, Royalties, Other Intellectual Property – PCT/EP2022/065222. Simple transcriptomic signatures to determine chemosensitivity for pancreatic ductal adenocarcinoma. SATT Sud-Est. Inventors: N. Dusetti, N. Fraunhoffer, J. Iovanna, 2021. Licensing to Predicting Med.
